Calcium antagonists and myocardial infarction

Area of Science:

• Cardiology
• Pharmacology

Background:

• Calcium antagonists (verapamil, nifedipine, diltiazem) exhibit similar myocardial protective effects in vitro and in vivo during hypoxia.
• Clinical applications during and after acute myocardial infarction (MI) reveal significant differences among these agents regarding mortality and reinfarction prevention.

Purpose of the Study:

• To compare the clinical efficacy of verapamil, nifedipine, and diltiazem in preventing death and reinfarction following acute myocardial infarction.
• To investigate the influence of beta-blocker therapy on the outcomes of calcium antagonist treatment post-MI.

Main Methods:

• Review of clinical trial data for verapamil, nifedipine, and diltiazem in acute MI and secondary prevention.
• Analysis of patient subgroups, including those treated with and without beta-blockers, and presence or absence of heart failure.

Main Results:

• Nifedipine showed no benefit over placebo during or after acute MI.
• Verapamil demonstrated improved survival and reduced reinfarction rates post-MI, particularly in patients without heart failure.
• Diltiazem's role in secondary prevention was inconclusive overall, but showed reduced cardiac events in patients without heart failure and increased events in those with heart failure.

Conclusions:

• Verapamil is indicated for secondary prevention post-MI in selected patients (without heart failure).
• Nifedipine currently has no established role during or after acute MI.
• Further research is needed for diltiazem, especially concerning its use in specific patient populations post-MI.